Key Takeaways: Arrowhead Research Corp (ARWR), Gold Resource Corporation (GORO) And Molycorp Inc (MCP)
New York, NY – GDP INSIDER – 12/31/2014.
Arrowhead Research Corp (NASDAQ:ARWR)’s RNAi drug projects have raised speculations that the company may be targeted for acquisition by some of the Big Pharma companies. Arrowhead Research has various drug development projects only that it failed to obtain expected results from a Phase 2a trial of its HBV drug candidate known as ARC-520.
However, the company continues to investment in drug development. In the most recent financial report, Arrowhead Research Corp (NASDAQ:ARWR) revealed a significant increase in spending that mostly related to research and development. The company’s total expenses for fiscal 2014 were $53.5 million, which increased from $24.9 million last year. New hires and clinical trial projects pushed up spending in 2014.
It is hoped that increased spending in R&D will eventually pay off as Arrowhead Research Corp (NASDAQ:ARWR) pushes its drug candidates to commercialization.
Gold Resource Corporation (NYSEMKT:GORO) intends to pay a cash dividend of $0.01 per share for the month of December. The declared monthly dividend will be paid on January 23 to shareholders of record on January 12.
Gold Resource Corporation (NYSEMKT:GORO) has been generous to its shareholders. It has returned more than $101 million to them since commencing commercial production in 2010. For the shareholders who desire to have their dividends in the form of physical commodities such
as gold and silver, GORO allows them to do just that.
Although Gold Resource Corporation (NYSEMKT:GORO) has already returned a significant amount of its gains to shareholders in the form of dividends, shareholders are yearning for more. They want the company to also initiate stock buyback, which will put more money in their hands.
Is GORO Ready To Make Even More 52 Week Highs Or Is A clomid online Retrace Coming? See Where GORO Is Going online Zoloft Next With A Free Trend Report
Rare earths company Molycorp Inc (NYSE:MCP) has had a rough time in 2014 with its share price being down more than 84% so what does abilify treat far. The issue of greater concern to investors is the company’s liquidity. Molycorp disclosed a huge debt of $1.6 billion at the end of its 3Q, during which it also reported a wider loss.
Molycorp Inc (NYSE:MCP) is faced with a $207 million debt that matures in mid-2016, yet the company revealed just about $314 million in cash at the end of the recent quarter.
UltimateStockAlerts.com provides investors and traders with trading strategies via text message and email. To obtain text message stock alerts service text the word ULTIMATE to 555888 from your cell phone.
UltimateStockAlerts continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
Disclosure: UltimateStockAlerts is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit www.UltimateStockAlerts.com website, for complete risks and disclosures.